Anavex Life Sciences Corp (AVXL)

[Steady_T]

Here is ACIU news. Note: It slowed the rate of decline and met one of two primary end points. Bolding is mine.

AC Immune SA on Tuesday said a Phase 2 study evaluating the safety and efficacy of its investigational anti-tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer's disease met one of its co-primary endpoints.

The Lausanne, Switzerland, clinical-stage biopharmaceutical company said semorinemab showed a statistically significant reduction in cognitive decline from baseline by 43.6% compared with placebo in the study. The study was being conducted by Roche Holding AG's Genentech unit, AC Immune's collaboration partner in Alzheimer's disease since 2006.

AC Immune said there was no effect on the other co-primary endpoint of reducing the rate of functional decline from baseline, adding that semorinemab was well tolerated in the study, with an acceptable safety profile and no unanticipated safety signals.

https://www.marketwatch.com/story/ac-immune-semorinemab-meets-co-primary-endpoint-in-alzheimer-s-disease-aciu-271630411441